Coeptis Therapeutics Holdings Inc (ZSQR) is a clinical-stage biopharmaceutical company focused on developing cell therapy and immunology product candidates for oncology. The company generates no product revenue, funding operations through equity and debt issuances while advancing a pipeline that includes SNAP-CAR T-cell technology licensed from the University of Pittsburgh and two CD38-targeted product candidates acquired through a co-development agreement with Vy-Gen. Coeptis completed a reverse merger with Bull Horn Holdings Corp. on October 28, 2022, with the legacy Coeptis Therapeutics, Inc. entity treated as the accounting acquirer. As of the 10-K filed March 19, 2026, the company had six employees (four full-time, two part-time), carried convertible notes payable including notes in default, held an SBA loan, and its independent auditors issued a going-concern opinion citing the need for additional capital to fund operations.

Revenue model

Pre-revenue. The company has no commercial products and no product sales. Operations are financed through capital raises, including equity offerings, preferred stock, and convertible notes. Future revenue, if any, is expected to come from royalties (3.5% of net sales under the University of Pittsburgh SNAP-CAR license) and potential partnership or commercialization agreements, none of which existed as of the filing date.

Products and services

SNAP-CAR T-cell platform: worldwide development and commercialization rights licensed from the University of Pittsburgh for human cancer treatment using antibody or antibody fragment-directed CAR T-cell technology; initial license fee of $75,000 paid, annual maintenance fees of $15,000 to $25,000, and a Sponsored Research Agreement entered in January 2023 to fund pre-clinical work. CD38-GEAR-NK: 50% co-ownership interest acquired from Vy-Gen, with purchase completed November 2022. CD38-Diagnostic: 50% co-ownership interest acquired from Vy-Gen, with purchase completed December 2021. Total payments to Vy-Gen included $750,000 in initial option payments (May 2021), $1,000,000 cash, and promissory notes aggregating $3,250,000.

Customers and end markets

No commercial customers as of the filing. End market is oncology, specifically solid tumors and CD38-expressing cancers. Clinical trial patients are the subject of enrollment efforts, not paying customers.

Value-chain role

Early-stage drug developer with no in-house commercial, sales, marketing, or distribution capabilities. Relies on academic and third-party research organizations for pre-clinical work (University of Pittsburgh SRA) and intends to partner with external firms for any future commercialization of FDA-approved products.

Geographic exposure

Worldwide development and commercialization rights held under the SNAP-CAR license. No commercial geographic footprint disclosed in the filing excerpts.

Source: SEC 10-K, filed 2026-03-19

Industry: Finance Services Peers: ABVC Biopharma Inc /entities/rdgad Cyclerion Therapeutics Inc Plus Therapeutics Inc Soligenix Inc Monopar Therapeutics Inc Moleculin Biotech Inc CERo Therapeutics Holdings Inc KINETA, INC./DE